RxDoctor Payments Data

Yaser Mustafa, MD

Hospitalist · Dekalb, ILNPI 1992217178

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Pfizer at 28.4% of the total. Reporting peaked in 2019 at $124 and has fallen 66.0% since, to $42 in 2024.

$186in general payments, 2019–2025

Across 10 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$53
  • Amgen$42
  • Abbott$28
  • Merck$27
  • Roche Diagnostics Corporation$22
  • GSK$14

What the payments were for

  • Food & beverage$186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$53
Amgen1$42
Abbott1$28
Merck2$27
Roche Diagnostics Corporation1$22
GSK1$14

How this compares

$186 in reported general payments places this provider in the 70th percentile of 1,328 hospitalist providers in Illinois.

See all hospitalist providers in Illinois

Medicare billing

Part B allowed, 2024
$103,884
Medicare patients
466
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$103,802
XareltoRivaroxaban46$55,853
OzempicSemaglutide33$42,558
JanuviaSitagliptin Phosphate27$41,886
TrulicityDulaglutide22$31,021
JardianceEmpagliflozin17$24,547
MyrbetriqMirabegron24$15,979
Breo ElliptaFluticasone/Vilanterol11$11,903
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$11,085
SymbicortBudesonide/Formoterol Fumarate21$6,207
Atorvastatin Calcium779$5,972
MovantikNaloxegol Oxalate13$5,608
Metoprolol Succinate299$4,202
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,306
Levothyroxine Sodium388$3,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$53$105,18497 claims
MerckJanuvia$27$41,88627 claims
GSKBreo Ellipta$14$11,90311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,328 hospitalist providers in Illinois.

Other hospitalist in Dekalb

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →